EBS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EBS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-21), Emergent BioSolutions's current share price is $5.18. Emergent BioSolutions's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $0.86. Emergent BioSolutions's Cyclically Adjusted Price-to-FCF for today is 6.02.
The historical rank and industry rank for Emergent BioSolutions's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
During the past years, Emergent BioSolutions's highest Cyclically Adjusted Price-to-FCF was 190.15. The lowest was 1.81. And the median was 77.17.
EBS's Cyclically Adjusted Price-to-FCF is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Emergent BioSolutions's adjusted free cash flow per share data for the three months ended in Mar. 2024 was $-1.406. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.86 for the trailing ten years ended in Mar. 2024.
The historical data trend for Emergent BioSolutions's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | 8.60 | 8.41 | 4.09 | 2.78 | 2.94 |
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Emergent BioSolutions's Cyclically Adjusted Price-to-FCF for today is calculated as
Cyclically Adjusted Price-to-FCF | = | Share Price | / | Cyclically Adjusted FCF per Share |
= | 5.18 | / | 0.86 | |
= | 6.02 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Emergent BioSolutions's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | -1.406 | / | 131.7762 | * | 131.7762 | |
= | -1.406 |
Current CPI (Mar. 2024) = 131.7762.
Emergent BioSolutions Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201406 | 0.157 | 100.560 | 0.206 |
201409 | 1.583 | 100.428 | 2.077 |
201412 | 0.949 | 99.070 | 1.262 |
201503 | -1.975 | 99.621 | -2.612 |
201506 | -0.171 | 100.684 | -0.224 |
201509 | 1.900 | 100.392 | 2.494 |
201512 | -0.209 | 99.792 | -0.276 |
201603 | 0.495 | 100.470 | 0.649 |
201606 | -0.573 | 101.688 | -0.743 |
201609 | 0.204 | 101.861 | 0.264 |
201612 | -0.643 | 101.863 | -0.832 |
201703 | 0.430 | 102.862 | 0.551 |
201706 | 0.893 | 103.349 | 1.139 |
201709 | 0.439 | 104.136 | 0.556 |
201712 | 1.278 | 104.011 | 1.619 |
201803 | -0.254 | 105.290 | -0.318 |
201806 | 0.410 | 106.317 | 0.508 |
201809 | 2.872 | 106.507 | 3.553 |
201812 | -3.588 | 105.998 | -4.461 |
201903 | 1.629 | 107.251 | 2.002 |
201906 | -0.969 | 108.070 | -1.182 |
201909 | -0.352 | 108.329 | -0.428 |
201912 | 1.632 | 108.420 | 1.984 |
202003 | 0.646 | 108.902 | 0.782 |
202006 | 1.735 | 108.767 | 2.102 |
202009 | 1.096 | 109.815 | 1.315 |
202012 | 3.844 | 109.897 | 4.609 |
202103 | -0.936 | 111.754 | -1.104 |
202106 | -1.791 | 114.631 | -2.059 |
202109 | -0.717 | 115.734 | -0.816 |
202112 | 5.277 | 117.630 | 5.912 |
202203 | -1.371 | 121.301 | -1.489 |
202206 | -0.954 | 125.017 | -1.006 |
202209 | -2.042 | 125.227 | -2.149 |
202212 | 1.390 | 125.222 | 1.463 |
202303 | -3.966 | 127.348 | -4.104 |
202306 | -2.503 | 128.729 | -2.562 |
202309 | 0.915 | 129.860 | 0.929 |
202312 | 0.397 | 129.419 | 0.404 |
202403 | -1.406 | 131.776 | -1.406 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Emergent BioSolutions's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Neal Franklin Fowler | director | C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
Donald W Degolyer | director | 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
William Hartzel | officer: SVP, Bioservices | 400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879 |
Miller H Haywood Iii | officer: Interim CEO | EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
Kathryn C Zoon | director | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Paul Anthony Williams | officer: SVP, Products Business | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Ronald Richard | director | 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850 |
Sujata Tyagi Dayal | director | C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587 |
Keith Katkin | director | C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617 |
Glessner Coleen | officer: EVP, Quality & Ethics, and CPL | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Jennifer Lynne Fox | officer: EVP, Ext Aff, GC, Corp Sec | 400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879 |
Richard S Lindahl | officer: EVP, Chief Financial Officer | NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191 |
Sue Bailey | director | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850 |
Adam Havey | officer: EVP, BioDefense Division | 2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853 |
Robert Kramer | officer: Interim, EVP, BioSciences | 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850 |
From GuruFocus
By Marketwired • 07-31-2023
By Stock market mentor Stock market mentor • 01-05-2023
By Value_Insider Value_Insider • 12-06-2022
By Marketwired • 10-19-2023
By sperokesalga sperokesalga • 05-11-2023
By Marketwired • 09-20-2023
By Stock market mentor Stock market mentor • 01-09-2023
By Marketwired • 07-25-2023
By Marketwired • 08-08-2023